Clinical Trial: The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07013149) titled 'The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension' on May 14.

Brief Summary: Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially fatal disease characterized by increased pulmonary vascular resistance and right ventricular dysfunction. Among the four major molecular pathways involved in PAH pathophysiology-nitric oxide, prostacyclin, activin, and endothelin-1 (ET-1)-the endothelin pathway plays a central role. Endothelin-1 acts on ETA and ETB receptors, inducing vasoconstriction and vascular remodeling.

Endothelin receptor antagonists (ERAs) are cornerstone therapies in P...